Literature DB >> 16318987

Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.

Adam P Kohm1, Danielle M Turley, Stephen D Miller.   

Abstract

A principal theme in autoimmunity is the breakdown of central tolerance resulting in the persistence and eventual activation of autoreactive T cells. Because CD4(+) T cells are key contributors to the underlying pathogenic mechanisms responsible for the onset and progression of most autoimmune diseases, they are a logical target for therapeutic interventions. One technique for restoring self-tolerance is to exploit the endogenous regulatory mechanisms that govern CD4(+) T-cell activation. In this review, we discuss promising techniques with the common goal of inducing antigen (Ag)-specific tolerance. Emphasis is given to the use of non-mitogenic anti-CD3 and peptide-specific tolerance strategies that specifically target the T-cell receptor (TCR) in the absence of costimulatory signals. These approaches produce a TCR signal of insufficient strength to cause CD4(+) T-cell activation and instead induce functional T-cell anergy or deletion while avoiding generalized long-term immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318987     DOI: 10.1080/08830180500371207

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  6 in total

1.  Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

Authors:  Daniel R Getts; Danielle M Turley; Cassandra E Smith; Christopher T Harp; Derrick McCarthy; Emma M Feeney; Meghann Teague Getts; Aaron J Martin; Xunrong Luo; Rachael L Terry; Nicholas J C King; Stephen D Miller
Journal:  J Immunol       Date:  2011-08-05       Impact factor: 5.422

2.  Endoplasmic reticulum stress response as a potential therapeutic target in multiple sclerosis.

Authors:  Meghann Teague Getts; Daniel R Getts; Adam P Kohm; Stephen D Miller
Journal:  Therapy       Date:  2008-09-01

3.  Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.

Authors:  Daniel R Getts; Aaron J Martin; Derrick P McCarthy; Rachael L Terry; Zoe N Hunter; Woon Teck Yap; Meghann Teague Getts; Michael Pleiss; Xunrong Luo; Nicholas J C King; Lonnie D Shea; Stephen D Miller
Journal:  Nat Biotechnol       Date:  2012-11-18       Impact factor: 54.908

Review 4.  Exploiting apoptosis for therapeutic tolerance induction.

Authors:  Daniel R Getts; Derrick P McCarthy; Stephen D Miller
Journal:  J Immunol       Date:  2013-12-01       Impact factor: 5.422

Review 5.  Genetically engineered T cells for cancer immunotherapy.

Authors:  Dan Li; Xue Li; Wei-Lin Zhou; Yong Huang; Xiao Liang; Lin Jiang; Xiao Yang; Jie Sun; Zonghai Li; Wei-Dong Han; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2019-09-20

Review 6.  Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Authors:  Georgina Flórez-Grau; Irati Zubizarreta; Raquel Cabezón; Pablo Villoslada; Daniel Benitez-Ribas
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.